Loading…
Lobbying Spend
—
Filings
40
Firms Hired
4
Active Period
2007–2013
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Preserve Access to Affordable Generics Act
2013 · second_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Oppose bills that prohibit brand name drug companies from settling patent litigation with generic drug companies and for other purposes. S. 214, Preserve Access to Affordable Generics Act.
Client expense: — · Firm income: $8,000
Matched citations: S. 214
Preserve Access to Affordable Generics Act
2013 · first_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Oppose bills that prohibit brand name drug companies from settling patent litigation with generic drug companies and for other purposes. S. 214, Preserve Access to Affordable Generics Act.
Client expense: — · Firm income: $28,000
Matched citations: S. 214
Protecting Consumer Access to Generic Drugs Act of 2012
2012 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Oppose bills that prohibit brand name drug companies from settling patent litigation with generic drug companies and for other purposes. S. 27, Preserve Access to Affordable Generics Act and H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012.
Client expense: — · Firm income: $36,000
Matched citations: H.R. 3995
Protecting Consumer Access to Generic Drugs Act of 2012
2012 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Oppose bills that prohibit brand name drug companies from settling patent litigation with generic drug companies and for other purposes. S. 27, Preserve Access to Affordable Generics Act and H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012.
Client expense: — · Firm income: $36,000
Matched citations: H.R. 3995
Protecting Consumer Access to Generic Drugs Act of 2012
2012 · second_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Oppose bills that prohibit brand name drug companies from settling patent litigation with generic drug companies and for other purposes. S. 27, Preserve Access to Affordable Generics Act and H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012.
Client expense: — · Firm income: $29,000
Matched citations: H.R. 3995
Protecting Consumer Access to Generic Drugs Act of 2012
2012 · first_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Oppose bills that prohibit brand name drug companies from settling patent litigation with generic drug companies and for other purposes. S. 27, Preserve Access to Affordable Generics Act and H.R. 3995, Protecting Consumer Access to Generic Drugs Act of 2012.
Client expense: — · Firm income: $15,000
Matched citations: H.R. 3995
Protecting Consumer Access to Generic Drugs Act of 2009
2010 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
H.R. 1706 and S. 369, Oppose bills that prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 1706
Preserve Access to Affordable Generics Act
2010 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
H.R. 1706 and S. 369, Oppose bills that prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Client expense: — · Firm income: $10,000
Matched citations: S. 369
Protecting Consumer Access to Generic Drugs Act of 2009
2010 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
H.R. 1706 and S. 369, Oppose bills that prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Client expense: — · Firm income: $15,000
Matched citations: H.R. 1706
Preserve Access to Affordable Generics Act
2010 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
H.R. 1706 and S. 369, Oppose bills that prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. Oppose legislation that prohibits settlement agreements between patent litigants that involve anything of value.
Client expense: — · Firm income: $15,000
Matched citations: S. 369
Community-Based Mental Health Infrastructure Improvements Act
2010 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
H.R. 4899, Supplemental Appropriations Act, 2010
Client expense: — · Firm income: —
Matched citations: H.R. 4899
Medicare, Medicaid, and SCHIP Extension Act of 2007
2007 · year_end · Firm: PARRY, ROMANI, DECONCINI & SYMMS
S. 1082, PDUFA Bill. S. 2499. Seek an approval process for antibiotics.
Client expense: — · Firm income: $60,000
Matched citations: S. 2499
Source: Senate LDA